2a
B-R
In patients with HFpEF, SGLT2i can be beneficial in decreasing HF hospitalizations and cardiovascular mortality.
Point of Care Answer
Expert Analysis
-
Expert Analysis The Emperor Finally Has Clothes! Insights from EMPEROR Preserved
Apr 20, 2022 -
Expert Analysis Pharmacologic Treatment For HFpEF: Role of Drug Therapies at the Higher End of LVEF Spectrum
Apr 11, 2022 -
Journal Scan Meta-Analysis of Trials of SGLT-2 Inhibitor Use in Heart Failure
Apr 11, 2022
Learning Opportunities
-
HFSAP
ProductHF SAP covers the entire field of advanced heart failure and transplant cardiology.
-
HFSAP Chapter
ChapterHFpEF Diagnosis, Pathophysiology, Etiology, and Management.
-
Watched
Video Video Presentation: HFpEF Diagnosis: Ruling Out MasqueradersJan 19, 2022
-
Visual Abstract EMPEROR-PreservedMar 4, 2022
-
Patient Case Quiz Unrecognized HFpEF in a Type 2 DM Patient - Reducing CV and HF Risk
Sara is a 65-year-old woman with long-standing type 2 diabetes mellitus (DM), hypertension, hyperlipidemia, and hypothyroidism...
Apr 1, 2022 -
Cardiology Magazine HFpEF: New Year, New Hope
Heart failure with preserved ejection fraction (HFpEF) has been called the greatest unmet need in cardiovascular medicine...
Apr 11, 2022
Foundational Research
-
Journal Scan Empagliflozin Improves Outcomes in Patients With HFpEF Irrespective of Age
Heart disease associated with diabetes mellitus (DM) continues to be the leading cause of death worldwide. ...
June 11, 2022 -
Clinical Trials EMPEROR-Preserved
The EMPEROR-Preserved trial showed that empagliflozin is superior to placebo in improving HF outcomes among patients with symptomatic stable HFpEF…
Jul 11, 2022 -
JACC Article Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. ...
Sep 11, 2022 -
Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER Trial)
Oct 11, 2022 -
JACC HF ArticlePrognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
Heart failure with preserved ejection fraction (HFpEF) is marked by increased left ventricular (LV) filling pressure, elevated LV stiffness, and prolonged relaxation in the presence ...
Nov 11, 2022
